Ash Birma's questions to Avadel Pharmaceuticals PLC (AVDL) leadership • Q2 2025
Question
An analyst from UBS, on behalf of Ash Birma, asked about the ongoing antitrust case against Jazz Pharmaceuticals. The questions focused on how Avadel substantiates the 1.5-year market entry delay and the implications of the lack of a summary judgment resolution.
Answer
CEO Gregory Divis declined to comment on specific matters related to the ongoing litigation, stating that details would become clearer closer to the scheduled jury trial, which is set to begin in under three months.